Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments

E-ISSN： 2212-3954|3|2|77-93

ISSN： 1574-8898

Source： Recent Patents on CNS Drug Discovery, Vol.3, Iss.2, 2008-06, pp. : 77-93

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Skeletal Effects of Central Nervous System Active Drugs: Anxiolytics, Sedatives, Antidepressants, Lithium and Neuroleptics

Current Drug Safety, Vol. 3, Iss. 3, 2008-09 ,pp. : 185-189

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments in Anxiety Disorders

Recent Patents on CNS Drug Discovery, Vol. 1, Iss. 3, 2006-11 ,pp. : 289-298

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments in Collagen Patents

Recent Patents on Regenerative Medicine, Vol. 2, Iss. 1, 2012-01 ,pp. : 1-10

Bentham Science Publishers

Access to resources Recommend Favorite

RECENT DEVELOPMENTS IN THE THERAPY OF GOUT

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 16, Iss. 5, 1968-05 ,pp. : 499-504

John Wiley & Sons Inc

Access to resources Recommend Favorite

Non-Peptide Arginine-Vasopressin Antagonists (Vaptans) for the Treatment of Hyponatremia in Neurocritical Care: A New Alternative?

By Fields Jeremy

Neurocritical Care, Vol. 11, Iss. 1, 2009-08 ,pp. : 1-4

Humana Press, Inc

Access to resources Recommend Favorite